• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evotec acquires Euprotec to augment anti-infectives platform

Evotec acquires Euprotec to augment anti-infectives platform

May 29, 2014
CenterWatch Staff

Evotec has acquired Euprotec, a U.K.-based specialist CRO. With a comprehensive portfolio of assays and disease models, Euprotec supports anti-infective drug discovery and development programs through to late stage preclinical investigation and clinical proof-of-concept studies.

The acquisition of Euprotec confirms Evotec's position as a fully integrated drug discovery and early development partner for pharma and biotechnology companies. Integration of Euprotec's unique capabilities augments and complements Evotec's high-end drug discovery platform with anti-infective screening, early PK/PD (pharmacokinetic/pharmacodynamic) profiling, an extensive range of disease and efficacy models for characterization of anti-bacterials, anti-fungals and anti-virals, StrainBank, a unique collection of clinical isolates, and core disease biology know-how in infection.

"Through the acquisition of Euprotec, Evotec expands its technological portfolio to offer a complete infrastructure and discovery solutions in infectious diseases," said Dr. Werner Lanthaler, CEO of Evotec. "Importantly, we acquire highly innovative approaches, within our core competence along the discovery value chain, to open new therapeutic routes in the major market of infectious diseases. There is a pressing need for new agents to treat key infections due to emerging resistance to current therapies. Currently, Evotec has two innovative programs, TargetPicV and TargetPGB, to develop drugs to treat infectious diseases, and with this acquisition we can expand this portfolio."

The purchase price consists of a cash consideration of $3.2 million and a deferred payment component of $2.1 million in cash. The deferred payment will be due following two years after the acquisition and depends upon the business performance and achieving certain revenue targets.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing